Comparing eye lymphoma treatments: injection vs radiation
Treatments studied
Part of Blood & lymphatic, Cancer, Eyes & vision clinical trials.
This study compares two treatments for a type of lymphoma in the eye area: injecting a drug called rituximab directly into the tumor versus using targeted radiation therapy. The goal is to see which treatment works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a slow-growing lymphoma in the eye area (MALT lymphoma).
- The lymphoma is limited to the eye area and hasn't spread to other parts of the body.
- You have not had treatment for this lymphoma before.
- You don't have other serious eye problems that would need surgery or affect vision tests.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for a slow-growing eye lymphoma called MALT lymphoma: a targeted injection (rituximab) directly into the tumor versus low-dose radiation. The goal is to see which is safer and works better, while avoiding whole-body side effects.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a short course of low-dose radiation (12 Gy in 6 sessions) to treat slow-growing lymphoma in the eye area. It aims to control the lymphoma while minimizing side effects.
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
This study tests a combination of a low dose of radiation and an oral targeted drug (orelabrutinib) for people with early-stage MALT lymphoma. The goal is to see if adjusting the treatment based on your response can be effective and reduce side effects.
This trial tests a treatment for primary vitreoretinal lymphoma, a rare eye cancer. It aims to see if the drug methotrexate can help patients with this condition.
Hear when a new Primary Ocular Adnexal MALT Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.